Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
Open Access
- 31 January 2019
- journal article
- letter
- Published by American Society of Hematology in Blood
- Vol. 133 (5), 494-497
- https://doi.org/10.1182/blood-2018-03-839688
Abstract
Publisher's Note: There is a Blood Commentary on this article in this issue.Keywords
This publication has 25 references indexed in Scilit:
- Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspectiveTherapeutic Advances in Hematology, 2015
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 studyLeukemia, 2015
- Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLLBlood, 2014
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsNew England Journal of Medicine, 2014
- The Role of Minimal Residual Disease Measurements in the Therapy for CLLHematology/Oncology Clinics of North America, 2013
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 TrialJournal of Clinical Oncology, 2012
- Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parametersBlood, 2010
- Chronic lymphocytic leukemia: planning for an aging population.Expert Review of Anticancer Therapy, 2010
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008